Reduction in colposcopy workload and associated clinical activity following human papillomavirus (HPV) catch-up vaccination programme in Scotland: an ecological study

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 124, Issue 9, 2017, Pages 1386-1393

  Cruickshank, M E ^a   Pan, J ^b   Cotton, S C ^a   Kavanagh, K ^b   Robertson, C ^b,c   Cuschieri, K ^d   Cubie, H ^d   Palmer, T ^e   Pollock, K G ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c HEALTH PROTECTION SCOTLAND   (United Kingdom)

^d Scottish Human Papillomavirus Reference Laboratory   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cervical screening; colposcopy; HPV; HPV vaccine; immunisation; loop excision

Indexed keywords

ADULT; ARTICLE; COLPOSCOPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PATIENT REFERRAL; PREDICTIVE VALUE; PRIORITY JOURNAL; SCOTLAND; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS; WORKLOAD; COMPLICATION; DIAGNOSTIC IMAGING; PAPILLOMAVIRUS INFECTION; PATHOLOGY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TRENDS; UTERINE CERVIX TUMOR; VIROLOGY;

WART VIRUS VACCINE;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; FEMALE; HUMANS; LOGISTIC MODELS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROCEDURES AND TECHNIQUES UTILIZATION; REFERRAL AND CONSULTATION; SCOTLAND; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; WORKLOAD;

EID: 85014777580     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.14562     Document Type: Article

References (20)

1. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Int J Cancer 2007;121:621–32.
2. Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014;348:1458.
3. [http://www.isdscotland.org/Health-Topics/Child-Health/Publications/2012-09-25/2012-09-25-HPV-Catchup-Report.pdf]. Accessed 10 January 2016.
4. Information Services Division. HPV Immunisation Uptake Rates: School Year 2014/15. 17 November 2015. [www.isdscotland.org/Health-Topics/Child-Health/publications/index.asp]. Accessed 23 April 2016.
5. Sinka K, Kavanagh K, Gordon R, Love L, Potts A, Donaghy M, et al. Achieving high and equitable coverage of adolescent HPV vaccine in Scotland. J Epidemiol Community Health 2014;68:57–63.
6. Kavanagh K, Pollock KGJ, Potts A, Love J, Cuschieri L, Cubie H, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPB16/18 and closely related HPV types. BJC 2014;110:2804–11.
7. Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, et al. HPV prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerg Infect Dis 2016;22:56–64.
8. Pollock KGJ, Kavanagh K, Potts A, Love J, Cuschieri L, Cubie H, et al. Reduction of low and high grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. BJC 2014;111:1824–30.
9. Palmer TJ, McFadden M, Pollock KGJ, Kavanagh K, Cuschieri K, Cruickshank M, et al. HPV immunisation and cervical screening; confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population based cohort study. BJC 2016;114:582–9.
10. [www.bsccp.org.uk/healthcare-professionals/recertification/9]. Accessed 10 January 2016.
11. Munro A, Gillespie C, Cotton S, Busby-Earle C, Kavanagh K, Cuschieri K, et al. The impact of HPV type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two centre observational study. BJOG 2016. doi: 10.1111/1471-0528.14563.
12. Osborne SL, Tabrizi SN, Brotherton JM, Cornall AM, Wark JD, Wrede CD, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine 2015;33:201–8.
13. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013;208:385–93.
14. Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. Vaccine 2015;33:1608–13.
15. [www.nsd.scot.nhs.uk/Documents/addendumnhscspdoc20v2.6may.pdf]. Accessed 23 April 2016.
16. Casey GM, Morris B, Burnell M, Parberry A, Singh N, Rosenthal AN. Celebrities and screening: a measurable impact on high-grade cervical neoplasia diagnosis from the ‘Jade Goody effect’ in the UK. Br J Cancer 2013;109:1192–7.
17. [www.bsccp.org.uk/assets/file/uploads/resources/NHSCSP_20_Colposcopy_and_Programme_Management_(3rd_Edition)_(2).pdf] Accessed 23 April 2016.
18. [www.nsd.scot.nhs.uk/services/Screening/cervicalscreening/index.html] Accessed 23 April 2016.
19. [www.nice.org.uk/guidance/dg4] Accessed 9 January 2016.
20. [www.nice.org.uk/advice/mib20/chapter/technology-overview] Accessed 9 January 2016.